Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 421

1.

Non-transferrin-bound iron during blood transfusion cycles in beta-thalassemia major.

Grosse R, Lund U, Caruso V, Fischer R, Janka GE, Magnano C, Engelhardt R, Dürken M, Nielsen P.

Ann N Y Acad Sci. 2005;1054:429-32.

PMID:
16339692
2.

Liver iron concentrations and urinary hepcidin in beta-thalassemia.

Origa R, Galanello R, Ganz T, Giagu N, Maccioni L, Faa G, Nemeth E.

Haematologica. 2007 May;92(5):583-8.

3.

Non-transferrin-bound labile plasma iron and iron overload in sickle-cell disease: a comparative study between sickle-cell disease and beta-thalassemic patients.

Koren A, Fink D, Admoni O, Tennenbaum-Rakover Y, Levin C.

Eur J Haematol. 2010 Jan 1;84(1):72-8. doi: 10.1111/j.1600-0609.2009.01342.x.

PMID:
19732137
4.

Serum non-transferrin-bound iron in beta-thalassaemia major patients treated with desferrioxamine and L1.

al-Refaie FN, Wickens DG, Wonke B, Kontoghiorghes GJ, Hoffbrand AV.

Br J Haematol. 1992 Oct;82(2):431-6.

PMID:
1419825
5.

The assessment of serum nontransferrin-bound iron in chelation therapy and iron supplementation.

Breuer W, Ronson A, Slotki IN, Abramov A, Hershko C, Cabantchik ZI.

Blood. 2000 May 1;95(9):2975-82.

6.

Kinetics of removal and reappearance of non-transferrin-bound plasma iron with deferoxamine therapy.

Porter JB, Abeysinghe RD, Marshall L, Hider RC, Singh S.

Blood. 1996 Jul 15;88(2):705-13.

7.

High nontransferrin bound iron levels and heart disease in thalassemia major.

Piga A, Longo F, Duca L, Roggero S, Vinciguerra T, Calabrese R, Hershko C, Cappellini MD.

Am J Hematol. 2009 Jan;84(1):29-33. doi: 10.1002/ajh.21317.

8.

Methods for noninvasive measurement of tissue iron in Cooley's anemia.

Sheth S, Tang H, Jensen JH, Altmann K, Prakash A, Printz BF, Hordof AJ, Tosti CL, Azabagic A, Swaminathan S, Brown TR, Olivieri NF, Brittenham GM.

Ann N Y Acad Sci. 2005;1054:358-72.

PMID:
16339684
9.

Timed non-transferrin bound iron determinations probe the origin of chelatable iron pools during deferiprone regimens and predict chelation response.

Aydinok Y, Evans P, Manz CY, Porter JB.

Haematologica. 2012 Jun;97(6):835-41. doi: 10.3324/haematol.2011.056317. Epub 2011 Dec 16.

10.
11.

Magnetic resonance screening of iron status in transfusion-dependent beta-thalassaemia patients.

Ooi GC, Khong PL, Chan GC, Chan KN, Chan KL, Lam W, Ng I, Ha SY.

Br J Haematol. 2004 Feb;124(3):385-90.

PMID:
14717788
12.

A simple model to assess and improve adherence to iron chelation therapy with deferoxamine in patients with thalassemia.

Pakbaz Z, Fischer R, Treadwell M, Yamashita R, Fung EB, Calvelli L, Quirolo K, Foote D, Harmatz P, Vichinsky EP.

Ann N Y Acad Sci. 2005;1054:486-91.

PMID:
16339703
13.

Oxidative status and malondialdehyde in beta-thalassaemia patients.

Cighetti G, Duca L, Bortone L, Sala S, Nava I, Fiorelli G, Cappellini MD.

Eur J Clin Invest. 2002 Mar;32 Suppl 1:55-60.

PMID:
11886433
14.

Bleomycin-detectable iron assay for non-transferrin-bound iron in hematologic malignancies.

von Bonsdorff L, Lindeberg E, Sahlstedt L, Lehto J, Parkkinen J.

Clin Chem. 2002 Feb;48(2):307-14.

15.

A randomized double-blind, placebo-controlled study of therapeutic effects of silymarin in β-thalassemia major patients receiving desferrioxamine.

Moayedi B, Gharagozloo M, Esmaeil N, Maracy MR, Hoorfar H, Jalaeikar M.

Eur J Haematol. 2013 Mar;90(3):202-9. doi: 10.1111/ejh.12061. Epub 2013 Jan 20.

PMID:
23278124
16.

No evidence for myocardial iron overload and free iron species in multitransfused patients with sickle/beta-thalassaemia.

Ghoti H, Goitein O, Koren A, Levin C, Kushnir T, Rachmilewitz E, Konen E.

Eur J Haematol. 2010 Jan 1;84(1):59-63. doi: 10.1111/j.1600-0609.2009.01355.x. Epub 2009 Sep 29.

PMID:
19793250
17.

A moderate transfusion regimen may reduce iron loading in beta-thalassemia major without producing excessive expansion of erythropoiesis.

Cazzola M, Borgna-Pignatti C, Locatelli F, Ponchio L, Beguin Y, De Stefano P.

Transfusion. 1997 Feb;37(2):135-40.

PMID:
9051086
18.

Urine biochemical markers of early renal dysfunction are associated with iron overload in beta-thalassaemia.

Koliakos G, Papachristou F, Koussi A, Perifanis V, Tsatra I, Souliou E, Athanasiou M.

Clin Lab Haematol. 2003 Apr;25(2):105-9.

PMID:
12641614
19.

Iron metabolism in thalassemia intermedia.

Fiorelli G, Fargion S, Piperno A, Battafarano N, Cappellini MD.

Haematologica. 1990 Sep-Oct;75 Suppl 5:89-95.

PMID:
2086386
20.

Desferrioxamine-chelatable iron (DCI), a component of serum non-transferrin-bound iron (NTBI) used for assessing iron chelation therapy.

Breuer W, Ermers MJ, Pootrakul P, Abramov A, Hershko C, Cabantchik ZI.

Transfus Sci. 2000 Dec;23(3):241-2. No abstract available.

PMID:
11099901

Supplemental Content

Support Center